I'm looking at a biopharmaceutical company currently (AKRO). The company's lead product is in clinical development and the results are due to be published this month. The CEO, who has been with the company since day 1, sold 250,000 shares and bought 0 in the past 12 months. Last week alone he sold 25,000 shares. There have been 4 insider buys in total over the past year, compared to 45 insider sells over the same timeframe. What do you think? Cause for concern?
https://hedgefollow.com/stocks/AKRO/insider-trading
Leave a Reply